FOLFOXIRI plus a is an ideal regimen for conversion in the treatment of advanced/recurrent colorectal cancer

Kazuma Kobayashi,Takuro Fujita,Yusuke Inoue,Satomi Okada,Toshiyuki Adachi,Sayaka Kuba,Michi Morita,Taiichiro Kosaka,Takayuki Tanaka,Shinichiro Kobayashi,Yasuhiro Maruya,Akihiko Soyama,Tomohiko Adachi,Minoru Fukuda,Takuya Honda,Shinichiro Ito,Masaaki Hidaka,Kengo Kanetaka,Susumu Eguchi

ANNALS OF ONCOLOGY（2022）

Cited 0|Views15

No score

Abstract

As treatment for advanced/recurrent colorectal cancer (ARCC), the introduction of doublet chemotherapy, represented by FOLFOX/FOLFIRI, and molecular-targeting agents, such as anti-VEGF antibody and anti-EGFR antibody, has given ARCC patients a more than three years' survival. Triplet chemotherapy, such as FOLFOXIRI+a, has already been used in daily practice. These regimens with powerful anti-tumor effects have enabled conversion, giving patients a longer survival than those without conversion. Therefore, we explored the ideal regimen for conversion, focusing on FOLFOXIRI+a.

Translated text

Key words

Metastatic Colorectal Cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined